Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: COVID-2019 therapeutics - Enanta Pharmaceuticals

Drug Profile

Research programme: COVID-2019 therapeutics - Enanta Pharmaceuticals

Alternative Names: Direct acting antivirals - Enanta Pharamceuticals

Latest Information Update: 30 Mar 2020

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antivirals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 13 Mar 2020 Early research in COVID-2019 infections in USA (unspecified route) before March 2020

Development Overview

Introduction

Direct-acting antiviral (DAA) Small molecule antiviral therapeutics are being developed by Enanta Pharmaceuticals for the treatment coronavirus (COVID-19). The therapeutics are being developed by taking a two-pronged approach to its COVID-19 discovery by testing compounds from Enanta's antiviral compound library for potential activity against COVID-19. It is also initiating a drug discovery program using its expertise in direct-acting antiviral mechanisms to discover new candidates to treat COVID-19. Early research is underway in the US.

Key Development Milestones

As of March 2020, early research for the development of small molecule antiviral therapeutics is ongoing in the US [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Small molecules
  • Mechanism of Action Undefined mechanism
  • WHO ATC code

    J05A (Direct acting antivirals)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA unspecified / unspecified Enanta Pharmaceuticals 13 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Enanta Pharmaceuticals Originator USA
Enanta Pharmaceuticals Owner USA

Development History

Event Date Update Type Comment
13 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (unspecified route) before March 2020 [1] Updated 30 Mar 2020

References

  1. Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19.

    Media Release
Back to top